3-(三氟甲基硫)苄溴 | 213203-84-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(三氟甲基硫)苄溴
• 中文别名: 3-(三氟甲基硫代)苄溴；3-(三氟甲硫基)溴苄
• 英文名称: 3-(Trifluoromethylthio)benzyl bromide
• 英文别名: 1-(bromomethyl)-3-(trifluoromethylsulfanyl)benzene
• CAS: 213203-84-0
• 化学式: C₈H₆BrF₃S
• mdl: MFCD00236346
• 分子量: 271.101
• InChiKey: MPZVFRHSCOOMNG-UHFFFAOYSA-N

物化性质

• 沸点：
  196.9±40.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  C
• 危险类别码：
  R34,R36
• 海关编码：
  2930909090
• 安全说明：
  S26,S36/37/39,S45

反应信息

• 作为反应物：
  描述：

  3-(三氟甲基硫)苄溴 、 (3α,5α)-3-hydroxy-3-(piperazin-1-ylmethyl)androstan-17-one 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以68%的产率得到(3α,5α)-3-hydroxy-3-[(4-(3-[(trifluoromethyl)sulfanyl]-benzyl)piperazin-1-yl)methyl]androstan-17-one
  参考文献：
  名称：

  Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3

  摘要：

  17Beta-hydroxysteroid dehydrogenase type 3 (17 beta-HSD3) is a steroidogenic enzyme that catalyzes the transformation of 4-androstene-3,17-dione (Delta(4)-dione) into androgen testosterone (T). To provide effective inhibitors of androgen biosynthesis, we synthesized two different series (amines and carbamates) of 3 beta-substituted-androsterone derivatives and we tested their inhibitory activity on 17 beta-HSD3. From the results of our structure-activity relationship study, we identified a series of compounds producing a strong inhibition of 17 beta-HSD3 overexpressed in HEK-293 cells (homogenized cells). The most active compound when tested in intact HEK-293 transfected cells, namely (3 alpha,5 alpha)-3-{[trans-2,5-dimethyl-4-{[2-(trifluoromethyl)phenyl] sulfonyl}piperazin-1-yl]methyl}-3-hydroxyandrostan-17-one (15b), shows an IC50 value of 6 nM, this compound is thus eight times more active than our reference compound D-5-2 (IC50 = 51 nM). This new improved inhibitor did not stimulate the proliferation of androgen-sensitive Shionogi cells, suggesting a non-androgenic profile. Compound 15b is thus a good candidate for further in vivo studies on rodents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.06.003

文献信息

• Chemical Compounds
  申请人：Turnbull Philip Stewart

  公开号：US20090170907A1

  公开（公告）日：2009-07-02

  This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.

  这项发明涉及非甾体化合物，它们是雄激素、糖皮质激素、矿质皮质激素和孕激素受体的调节剂，以及这些化合物的制备和使用方法。
• [EN] GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY<br/>[FR] COMPOSES MODULATEURS DE RECEPTEURS DE GLUCOCORTICOIDE ET PROCEDES
  申请人：LIGAND PHARM INC

  公开号：WO2005082909A1

  公开（公告）日：2005-09-09

  Provided herein are compounds of Formula (I) and pharmaceutically acceptable derivatives thereof. Certain of such compounds are selective glucocorticoid receptor modulators and/or selective glucocorticoid binding agents. Also provided are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

  本文提供了式（I）的化合物及其药用可接受的衍生物。其中某些化合物是选择性糖皮质激素受体调节剂和/或选择性糖皮质激素结合剂。还提供了制备和使用这些化合物的方法，包括但不限于使用这些化合物治疗各种疾病。
• Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
  申请人：Gallant Michel

  公开号：US20050245513A1

  公开（公告）日：2005-11-03

  8-arylquinolines wherein the aryl group at the 8-position contains a meta one or two atom bridge to a phenyl, 5 or 6 member heteroaryl or fused bicyclic heteroaryl group, and wherein at least one of the bridge atoms is not carbon, are PDE4 inhibitors.

  8-芳基喹啉中，位于8位的芳基基团包含一个与苯、5或6成员杂环芳基或融合的双环杂环芳基群之间的一个或两个原子桥，且至少有一个桥中的原子不是碳，它们是PDE4抑制剂。
• Glucocorticoid receptor modulator compounds and methods
  申请人：Zhi Lin

  公开号：US20070281959A1

  公开（公告）日：2007-12-06

  Disclosed herein are compounds of Formula I: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. Certain of such compounds are selective glucocorticoid receptor modulators and/or selective glucocorticoid binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

  本文公开了I式化合物及其药物可接受的盐、酯、酰胺和前药。其中某些化合物是选择性糖皮质激素受体调节剂和/或选择性糖皮质激素结合剂。还公开了制备和使用这些化合物的方法，包括但不限于使用这些化合物治疗各种疾病的方法。
• Glucocorticoid Receptor Modulator Compounds and Methods
  申请人：Zhi Lin

  公开号：US20090105292A9

  公开（公告）日：2009-04-23

  Disclosed herein are compounds of Formula I: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. Certain of such compounds are selective glucocorticoid receptor modulators and/or selective glucocorticoid binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

  本文公开了I式化合物及其药物可接受的盐，酯，酰胺和前药。其中某些化合物是选择性糖皮质激素受体调节剂和/或选择性糖皮质激素结合剂。还公开了制备和使用这些化合物的方法，包括但不限于使用这些化合物治疗各种疾病。